China SXT Pharmaceuticals, Inc.
SXTC
$2.86
$0.3714.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.82M | 1.87M | 1.93M | 1.82M | 1.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.82M | 1.87M | 1.93M | 1.82M | 1.70M |
| Cost of Revenue | 1.42M | 1.40M | 1.37M | 1.23M | 1.08M |
| Gross Profit | 400.40K | 477.20K | 554.00K | 589.50K | 625.00K |
| SG&A Expenses | -6.22M | -1.79M | 2.65M | 8.36M | 14.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.80M | -389.60K | 4.02M | 9.59M | 15.16M |
| Operating Income | 6.62M | 2.26M | -2.09M | -7.77M | -13.46M |
| Income Before Tax | 5.80M | 1.35M | -3.10M | -8.62M | -14.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.80 | 1.35 | -3.10 | -8.62 | -14.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.80M | 1.35M | -3.10M | -8.62M | -14.14M |
| EBIT | 6.62M | 2.26M | -2.09M | -7.77M | -13.46M |
| EBITDA | 6.79M | 2.45M | -1.89M | -7.55M | -13.21M |
| EPS Basic | 40.81 | -35.54 | -111.89 | -174.44 | -236.98 |
| Normalized Basic EPS | 27.22 | -20.50 | -68.22 | -106.14 | -144.07 |
| EPS Diluted | 40.81 | -35.54 | -111.89 | -174.44 | -236.98 |
| Normalized Diluted EPS | 27.22 | -20.50 | -68.22 | -106.14 | -144.07 |
| Average Basic Shares Outstanding | 1.12M | 775.00K | 433.80K | 333.60K | 233.40K |
| Average Diluted Shares Outstanding | 1.12M | 775.00K | 433.80K | 333.60K | 233.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
